A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
